Showing results (601-610 of 782) with videos related to

Sort By:
Pageof 79
Blood|May 4, 2007
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphismEvdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, et al.
Haematologica|June 30, 2011
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myelomaJana Jakubikova, David Cervi, Melissa Ooi, et al.
Blood|May 16, 2009
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myelomaAbdel Kareem Azab, Feda Azab, Simona Blotta, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Cancer Cell|April 10, 2007
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesisDaniel R Carrasco, Kumar Sukhdeo, Marina Protopopova, et al.
American Journal of Hematology|January 22, 2024
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myelomaXuehan Mao, Wenqiang Yan, David Mery, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
British Journal of Haematology|June 3, 2015
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinationsCindy Varga, Wanling Xie, Jacob Laubach, et al.
Blood|February 16, 2011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsJana Jakubikova, Sophia Adamia, Maria Kost-Alimova, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
Pageof 79